VK-2809 is under clinical development by Viking Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect VK-2809’s likelihood of approval (LoA) and phase transition for Hypercholesterolemia took place on 11 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 11 Dec 2020 increased VK-2809’s Phase Transition Success Rate (PTSR) for Non Alcoholic Fatty Liver Disease (NAFLD).
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their VK-2809 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
VK-2809 (MB-07811) is under development for the treatment of hypercholesterolemia, non-alcoholic steatohepatitis (NASH), fibrosis and non alcoholic fatty liver disease (NAFLD), The drug candidate is formulated as capsule and is administered orally. It targets thyroid hormone receptor beta (TR-Beta). It is a prodrug of MB-07344. The drug candidate is developed based on HepDirect liver-targeting technology platform. It was also under development for the treatment of glycogen storage disease type 1a and and X-linked adrenoleukodystrophy.
Viking Therapeutics overview
Viking Therapeutics is clinical-stage biopharmaceutical company that develops novel therapies for patients suffering from metabolic and endocrine disorders. The company lead clinical program product candidate include VK5211, an orally available, non-steroidal selective androgen receptor modulator developed for the treatment of lean body mass loss in patients who have undergone hip fracture surgery. Its other pipeline product candidates include VK0214 for the treatment of orphan indication, a rare X-linked inherited neurological disorder; VK2809 developed for orally available tissue and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease and VK0612, an inhibitor of fructose -1,6-biphosphatase for type 2 diabetes. Viking Therapeutics is headquartered in San Diego, California, the US.
Quick View VK-2809 LOA Data
|Highest Development Stage|